Home » Stocks » INZY

Inozyme Pharma, Inc. (INZY)

Stock Price: $26.97 USD 0.74 (2.80%)
Updated November 30, 2:27 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 630.25M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 23.37M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $26.97
Previous Close $26.23
Change ($) 0.74
Change (%) 2.80%
Day's Open 26.08
Day's Range 25.88 - 26.97
Day's Volume 8,453
52-Week Range 17.54 - 30.20

More Stats

Market Cap 630.25M
Enterprise Value 471.66M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.37M
Float n/a
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 583,789
Short Ratio 13.29
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.65
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 158.59M
Net Cash / Share 6.79
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(35.99% upside)
Current: $26.97
Target: 36.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-20.81-11.59
Net Income-19.72-6.96
Shares Outstanding1.181.05
Earnings Per Share-16.67-6.63
Operating Cash Flow-18.81-9.44
Capital Expenditures-0.14-0.26
Free Cash Flow-18.95-9.70
Cash & Equivalents47.2643.16
Net Cash / Debt47.2643.16
Book Value-33.22-13.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inozyme Pharma, Inc.
Country United States
CEO Axel Bolte

Stock Information

Ticker Symbol INZY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: INZY
IPO Date July 24, 2020


Inozyme Pharma, a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as in the early stages of development for calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.